Trial Profile
Phase IIA, Single-Center, Single-Arm Clinical Study of OMN54 (Aneustat) in Men Diagnosed With Prostate Cancer Being Followed by Active Surveillance
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2021
Price :
$35
*
At a glance
- Drugs OMN 54 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CAMPAS
- Sponsors Omnitura Therapeutics
- 14 Oct 2021 Planned End Date changed from 1 Dec 2022 to 1 Jan 2029.
- 14 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Jan 2028.
- 14 Oct 2021 Planned initiation date changed from 1 Jan 2021 to 1 Jan 2025.